Cytarabine, Daunorubicin

7 trials 3 recruiting LOncology Orphan designation

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

3 Recruiting

4 Completed trials

6 Sponsors

11 Countries

Phase III

Phase II

Phase I (Other)

Phase III: 3 Phase II: 3 Phase I (Other): 1

Oversight events:

11 temporary halts across 2 trials

View oversight register →

Sponsors using this IMP

GPOH gGmbH 2 Centre Hospitalier Universitaire De Nantes 1 GWT-Tud GmbH 1 Prinses Maxima Centrum voor Kinderoncologie B.V. 1 Universitaet Leipzig 1 Universitaetsklinikum Ulm AöR 1

All trials

7 total

VyClo ITCC-092 Recruiting

2023-508050-26-00 Phase I (Other) 6 countries Prinses Maxima Centrum voor Kinderoncologie B.V.
International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Recruiting

2022-500783-35-00 Phase III 6 countries GPOH gGmbH
CPX-351 versus intensive chemotherapy in patients with de novo intermediate or adverse risk AML stratified by genomics Recruiting

2022-500295-60-00 Phase II 1 country Centre Hospitalier Universitaire De Nice
Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018 Ended

2022-501457-37-00 Phase III 7 countries GPOH gGmbH
Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagno… Ended

2023-503670-21-00 Phase III 2 countries Universitaetsklinikum Ulm AöR
Comparison of therapies before stem cell transplantation in patients with higher risk MDS and oligoblastic AML Ended

2024-515375-35-00 Phase II 2 countries GWT-Tud GmbH
Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem … Ended

2022-502040-13-00 Phase II 1 country University of Leipzig

Showing 1–7 of 7 trials

← All drugs A–Z